Articles by Hellen Berger - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Hellen Berger

Hellen Berger


Hellen Berger is a business writer based in Sao Paulo, Brazil.

Articles
Economic Growth Stalls in Brazil
October 2, 2014

Brazil's pharmaceutical industry is optimistic, but is the pharmaceutical market growing steadily or showing signs of instability?

Brazil's Phytotherapic Drug Market and Regulation
July 2, 2014

Is there potential for growth in Brazil's phytotherapic drug market?

Global Instability Impacts Brazil's Pharma Market
May 2, 2014

How badly is Brazil's pharmaceutical market suffering from the global instability of emerging markets?

Global Instability Affects the Pharma Market in Brazil
April 2, 2014

How badly is Brazil's pharmaceutical market suffering from the global instability of emerging markets?

Innovation and Market Growth in Brazil
January 2, 2014

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator.

Report from Brazil
November 2, 2013

New regulation offers patients in Brazil greater access to experimental drugs.

Report from Brazil
September 2, 2013

Pharma eyes biologics production in Brazil as the government begins to recognize the potential of these drugs.

Report from Brazil
July 2, 2013

Brazil offers opportunities and challenges for global pharmaceutical companies.

Report from Brazil
May 2, 2013

Prior to price escalation of pharmaceutical products in Brazil, the country's regulatory authority released a study on price-cap control and its benefits in the past years.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here